Trial finds GSK Ebola shot is safe and
provokes immune response
Send a link to a friend
[January 29, 2015]
By Kate Kelland
LONDON (Reuters) - First results from a
human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and
generates an immune response, scientists said on Wednesday, but larger
trials are needed to see if it protects and if a booster is needed.
|
The vaccine is being developed by the U.S. National Institutes of
Health (NIH) and GSK against the Zaire strain of Ebola -- the one
circulating in West Africa -- and the first doses for a larger trial
arrived in Liberia last week.
That trial is the first of several mid-stage studies planned for
West Africa and aims to test GSK's vaccine and one from Merck and
NewLink. Johnson & Johnson and Bavarian Nordic have a vaccine in
early-stage clinical tests.
The early-stage Phase I trial of GSK's vaccine was primarily
designed to test safety, but Adrian Hill, who led the work at
Oxford's Jenner Institute, said it was "encouraging" that the shot
also prompted responses from the immune system.
"The safety profile is pretty much as we'd hoped and the immune
responses are okay, but not great," he told Reuters.
The data, published in the New England Journal of Medicine, were
from 60 healthy volunteers given the vaccine in Britain between
Sept. 17 and Nov. 18 last year.
The volunteers got one of three doses - low, medium, or high - and
data from 28 days after vaccination showed the shot was safe at
these doses, with only mild side effects.
"People typically experienced mild symptoms that lasted for one or
maybe two days, such as pain or reddening at the injection site, and
occasionally people felt feverish," Hill said.
However, the antibody response was weaker than was found in a trial
of the same Ebola vaccine in macaque monkeys, in which the animals
were also found to be protected.
[to top of second column] |
Hill said the lower antibody levels, together with a lower response
detected in the immune system's T-cells, suggested to him that a
booster may well be needed.
Jeremy Farrar, director of the Wellcome Trust charity which helped
fund the trial, said it provided "good initial evidence that the GSK
vaccine will be safe to use in people".
"However, we still don't know whether it will provide protection
against Ebola infection in a real-world situation," he said. "That's
why trials in West Africa of this, and the other vaccines in
development, must begin as soon possible."
(Editing by Louise Ireland)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|